Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINI-STAR
NCT07871604Phase 4Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Nov 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 4, randomised trial in atherosclerosis comparing Rosuvastatin/ezetimibe 2.5/10mg, Atorvastatin/ezetimibe 5/10mg and Pitavastatin/ezetimibe 1/10mg (3 arms). Primary endpoint: Discontinuation or drug change of the study drug due to intolerance at 1 year. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
rosuvastatinatorvastatinpitavastatinezetimibe
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT07871604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871604.